Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2451 to 2500 of 2995 results for all

  1. What are the long-term outcomes of different management strategies for primary hyperparathyroidism? Which strategies are most cost effective?

    specialist endocrine opinion on monitoring. All people with primary hyperparathyroidism For all people with primary...

  2. Type 1 diabetes in adults (QS208)

    This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.

  3. Acute kidney injury (QS76)

    This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

  4. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  5. Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour (HTG744)

    Evidence-based recommendations on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. This involves inserting a silicone balloon into the vagina and inflating to lift the baby’s head before starting the caesarean.

  6. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

  7. What local anaesthetic techniques are most effective for women having surgical abortion?

    during it. With this in mind, the committee recommended discussing all the anaesthesia options and explaining the differences to the...

  8. Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus (MIB5)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Acoustic CR Neuromodulation system

  9. Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.

  10. Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

    Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.

  11. Mepolizumab for treating severe eosinophilic asthma (TA671)

    Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.

  12. StoneChecker for kidney stone evaluation (MIB171)

    NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .

  13. Novii Wireless Patch System for maternal and fetal monitoring (MIB228)

    NICE has developed a medtech innovation briefing (MIB) on Novii Wireless Patch System for maternal and fetal monitoring .

  14. Macimorelin for diagnosing growth hormone deficiency (MIB320)

    NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .

  15. Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)

    NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .

  16. Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

    Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.

  17. Emergency and acute medical care in over 16s: service delivery and organisation (NG94)

    This guideline covers organising and delivering emergency and acute medical care for people aged over 16 in the community and in hospital. It aims to reduce the need for hospital admissions by giving advanced training to paramedics and providing community alternatives to hospital care. It also promotes good-quality care in hospital and joint working between health and social services.

  18. Stable angina: management (CG126)

    This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.

  19. iFuse for treating chronic sacroiliac joint pain (HTG488)

    Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain.

  20. SEM Scanner 200 for preventing pressure ulcers (HTG556)

    Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.

  21. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

    Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

  22. Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people with multimorbidity who may not benefit from continuing them?

    with limited life expectancy). Discontinuation could either be complete (all relevant medicines) or partial (for example, reduced...

  23. VA ECMO for postcardiotomy cardiogenic shock in adults (HTG762)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  24. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)

    Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.

  25. Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

    Evidence-based recommendations on iptacopan (Fabhalta) for treating paroxysmal nocturnal haemoglobinuria in adults.

  26. Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

    Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

  27. The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

    NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system

  28. Hypertension in adults: diagnosis and management (NG136)

    This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.

  29. NICE Listens

    NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social value issues.

  30. Minimally invasive video-assisted thyroidectomy (HTG349)

    Evidence-based recommendations on minimally invasive video-assisted thyroidectomy. This involves inserting instruments through a small cut (keyhole surgery) to remove part or all of the gland.

  31. CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment (HTG663)

    Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.

  32. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

  33. In women with type 1 diabetes who are planning to become pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring intermittent capillary blood glucose monitoring?

    that would still be needed to use flash safely. The committee agreed that all the uncertainties in the evidence would be likely to lead...

  34. In women with type 1 diabetes who are already pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring?

    that would still be needed to use flash safely. The committee agreed that all the uncertainties in the evidence would be likely to lead...

  35. Can risk of contrast-induced acute kidney injury be stratified by eGFR thresholds?

    at particularly high risk and that oral hydration should be encouraged in all other adults at increased risk of contrast-induced acute...

  36. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  37. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  38. What is the relative effectiveness and cost effectiveness of different oral fluids and different oral fluid regimens, both with and without oral N-acetylcysteine, at preventing contrast-induced acute kidney injury?

    at particularly high risk and that oral hydration should be encouraged in all other adults at increased risk of contrast-induced acute...

  39. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

  40. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

  41. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

  42. Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

    Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.

  43. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

    Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

  44. What interventions are effective and cost effective in supporting return to work after recurrent short-term sickness absence in the UK?

    they are properly implemented. The committee agreed that it is important for all sizes of organisation to clearly communicate policies...

  45. Community pharmacies: promoting health and wellbeing (QS196)

    This quality standard covers how community pharmacies can support the health and wellbeing of the local population. It describes high-quality care in priority areas for improvement.

  46. Spondyloarthritis (QS170)

    This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

  47. Flu vaccination: increasing uptake (QS190)

    This quality standard covers increasing the uptake of flu vaccination among people who are eligible. It describes high-quality care in priority areas for improvement.

  48. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

  49. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

  50. Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

    Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.